References
sanofi-aventis. Sanofi-aventis receives a non approvable letter from the FDA for dronedarone (MULTAQ(tm)) in the treatment of Atrial Fibrillation/Atrial Flutter. Media Release: 31 Aug 2006. Available from URL: http://www.sanofi-aventis.com
sanofi-aventis. Analysis From Several Clinical Studies Show Dronedarone Appears to Be Consistently Safe and Effective in Maintaining Normal Sinusal Rhythm and Ventricular Rate Control in Patients With Cardiac Arrhythmia. Media Release: 15 Nov 2005. Available from URL: http://www.sanofi-aventis.com
Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. European Heart Journal 24: 1481–1487, Aug 2003
Sanofi-Synthelabo. Sanofi-Synthelabo Outstanding 2003 Performance. Media Release: 16 Feb 2004. Available from URL: http://www.sanofi-synthelabo.com
European Society of Cardiology. ESC Congress 2004: Benefits of dronedarone in management of cardiac arrhythmia. Results of the EURIDIS trial announced at the European Society of Cardiology 2004 Congress. Media Release: 29 Aug 2004. Available from URL: http://www.eurekalert.org
Van Horn R, Brian W. Assessing the potential for co-administered drugs to inhibit the N-debutylation of SR 33589B using human liver microsomes. 7th North American ISSX Meeting 10: 393, 20 Oct 1996
Chen F, Sun W, Ding S, et al. Dronedarone alters calcium current kinetics in isolated mouse ventricular myocytes. Pediatric Research 47 (Suppl.): 39, Part 2, Apr 2000
Sun W, Sarma JSM, Ding S, et al. Dronedarone acutely inhibits L-type calcium currents and alters the channel kinetics in rabbit ventricular myocytes. Journal of the American College of Cardiology 37 (Suppl. A): 114, Feb 2001
Chatelain P, Meysmans L, Mattéazzi JR, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. British Journal of Pharmacology 116: 1949–1956, Oct 1995
Varró A, Papp JG. The cellular cardiac electrophysiological effects of dronedarone, a new amiodarone like antiarrhythmic agent. Cardiovascular Drugs and Therapy 14: 200, Mar 2000
Guillemare E, Marion A, Nisato D, et al. Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells. Journal of Cardiovascular Pharmacology 36: 802–805, Dec 2000
Manning A, Hodeige D, Richard J. SR33589, a new amiodarone-like Antiarrhythmic agent: electrophysiological effects in dogs. British Journal of Pharmacology 112 (Suppl.): abstr. 579P, Jul 1994
Manning AS, Bruyninckx C, Hodeige D. SR 33589: a new amiodarone-like antiarrhythmic agent. British Journal of Pharmacology 107 (Suppl.): 270, Dec 1992
Iacour C, Canals F, Galindo G, et al. Amiodarone and dronedarone exert a wide inhibition of the vasoconstrictive effect of various neurohormones. European Journal of Heart Failure 2 (Suppl. 2): 56, Jun 2000
Finance O, Manning AS, Chatelain P. SR 33589B, a new amiodarone-like agent: effect on ischaemia-induced ventricular arrhythmias in anaesthetized pigs. British Journal of Pharmacology 111 (Suppl.): abstr. 28P, Jan 1994
Manning AS, Bruyninckx C, Ramboux J, et al. SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. Journal of Cardiovascular Pharmacology 26: 453–461, Sep 1995
Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. Journal of Cardiovascular Pharmacology 26: 570–576, Oct 1995
Verduyn SC, Leunissen JD, Vos MA. Intravenous administration of an amiodarone like agent, dronedarone (SR33589), does not evoke but suppresses torsade de pointes arrhythmias. Circulation 94 (Suppl.): 745, 15 Oct 1996
Djandjighian L, Planchenault J, Finance O, et al. Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction. Journal of Cardiovascular Pharmacology 36: 376–383, Sep 2000
Sun W, Sarma JSM, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. Journal of Cardiovascular Pharmacology 39: 677–684, May 2002
European Society of Cardiology. ESC Congress 2004: Dronedarone is effective and well-tolerated in prevention of AF recurrence. Media Release: 29 Aug 2004. Available from URL: http://www.eurekalert.org
Connolly SJ, Roy D, EURIDIS and ADONIS Investigators. Randomized trials of dronedarone for maintenance of sinus rhythm in atrial fibrilation or flutter: EURIDIS and ADONIS. Canadian Journal of Cardiology 20 (Suppl. D): 197–198, Oct 2004
Rights and permissions
About this article
Cite this article
Dronedarone. Drugs R D 8, 171–175 (2007). https://doi.org/10.2165/00126839-200708030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200708030-00004